News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
..only $170M market cap, sell to highest bidder! ME$$,,,
It doesn’t bother me, since I have lots of money to buy shares of a company like Curtis-Wright
ME new 52 lo
ME new 52 week low
ME new 52 week low
ME new 52 week low
ME new 52 week low
ME new 52 week low
23andMe Holding Co. NASDAQ: ME
GoSymbol lookup
Health Care : Health Care Providers & Services | Small Cap BlendCompany profile
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
|
Followers
|
20
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
163
|
|
Created
|
11/30/20
|
Type
|
Free
|
| Moderators | |||
Most people know 23andMe (NASDAQ:ME) for its consumer-facing genetics testing kits,
and while this is certainly an excellent revenue stream, it's not the most exciting part of the company's business.
Where the real long-term potential lies is in the massive genetics data library the company has accumulated, with nearly 12 million genotyped individuals.
To put this in context, consider that the second-largest collection of genetic data belongs to Regeneron Pharmaceuticals, which has less than 10% of this amount.
Here's the point. 23andMe has a 50-50 partnership with pharmaceutical giant GlaxoSmithKline to leverage the company's genetics information to develop therapeutics.
The company currently has some exciting candidates, and if successful,
this could easily be a multibillion-dollar revenue stream for 23andme, which is currently valued at just $3.3 billion.
65 Bleecker Street
6th Floor
New York, NY 10012
| FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
|---|---|---|---|
| 4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
| 4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
| 4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
| 4 | 12/10/2020 | 12/08/2020 | PDFRTFHTMLXLS |
| 4/A | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
| 4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
| 8-K | 11/20/2020 | 11/20/2020 | PDFRTFHTMLXLS |
| 10-Q | 11/16/2020 | 09/30/2020 | PDFRTFHTMLXLS |
| 8-K | 10/22/2020 | 10/16/2020 | PDFRTFHTMLXLS |
| 8-K | 10/13/2020 | 10/06/2020 | PDFRTFHTMLXLS |
